Source:http://linkedlifedata.com/resource/pubmed/id/19896085
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0005961,
umls-concept:C0013018,
umls-concept:C0018133,
umls-concept:C0025677,
umls-concept:C0030705,
umls-concept:C0085145,
umls-concept:C0085149,
umls-concept:C0199176,
umls-concept:C0281560,
umls-concept:C0445356,
umls-concept:C1274040,
umls-concept:C1514756,
umls-concept:C1527169,
umls-concept:C1883018
|
| pubmed:issue |
12
|
| pubmed:dateCreated |
2009-11-9
|
| pubmed:abstractText |
Tacrolimus (FK) and cyclosporine (CsA) have been shown to be effective in the prophylaxis of graft-versus-host disease (GVHD). However, no comparative studies have yet been conducted to examine the efficacy of FK/methotrexate (MTX) and CsA/MTX in patients with severe aplastic anemia (SAA) given unrelated donor bone marrow transplantation (U-BMT). We used matched-pair analysis to compare FK/MTX with CsA/MTX in patients with SAA who received U-BMT through the Japan Marrow Donor Program. Forty-seven pairs could be matched exactly for recipient age and conditioning regimens. Forty-five patients achieved engraftment in the FK group and 42 patients in the CsA group. The probability of grade II-IV acute GVHD (aGVHD) was 28.9% in the FK group and 32.6% in the CsA group (P=.558). The probability of chronic GVHD (cGVHD) was 13.3% in the FK group and 36.0% in the CsA group (P=.104). The 5-year survival rate was 82.8% in the FK group and 49.5% in the CsA group (P=.012). The study shows the superiority of FK/MTX over CsA/MTX in overall survival because of the lower incidence of transplantation-related deaths. A prospective randomized study comparing FK/MTX and CsA/MTX is warranted.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1523-6536
|
| pubmed:author |
pubmed-author:KatoKojiK,
pubmed-author:KatoShunichiS,
pubmed-author:KawaseTakakazaT,
pubmed-author:KigasawaHisatoH,
pubmed-author:KoderaYoshihisaY,
pubmed-author:KojimaSeijiS,
pubmed-author:MorishimaYasuoY,
pubmed-author:MuramatsuHidekiH,
pubmed-author:SakamakiHisashiH,
pubmed-author:TsuchidaMasahiroM,
pubmed-author:YabeHiromasaH,
pubmed-author:YagasakiHiroshiH
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1603-8
|
| pubmed:meshHeading |
pubmed-meshheading:19896085-Anemia, Aplastic,
pubmed-meshheading:19896085-Bone Marrow Transplantation,
pubmed-meshheading:19896085-Cyclosporine,
pubmed-meshheading:19896085-Female,
pubmed-meshheading:19896085-Graft vs Host Disease,
pubmed-meshheading:19896085-Humans,
pubmed-meshheading:19896085-Immunosuppressive Agents,
pubmed-meshheading:19896085-Male,
pubmed-meshheading:19896085-Matched-Pair Analysis,
pubmed-meshheading:19896085-Methotrexate,
pubmed-meshheading:19896085-Survival Rate,
pubmed-meshheading:19896085-Tacrolimus,
pubmed-meshheading:19896085-Tissue Donors
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis.
|
| pubmed:affiliation |
Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
|
| pubmed:publicationType |
Journal Article
|